81976-73-0

Basic information

• Product Name: 4-phenylpiperidin-2-one
• Synonyms: 4-Phenyl-2-piperidinone;2-Piperidinone, 4-phenyl-
• CAS NO: 81976-73-0
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175
• Mol File: 81976-73-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 137-139 °C
• Boiling Point: 372.7±31.0 °C(Predicted)
• Appearance: /
• Density: 1.073±0.06 g/cm3(Predicted)
• PKA: 16.25±0.40(Predicted)
• CAS DataBase Reference: 4-phenylpiperidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-phenylpiperidin-2-one(81976-73-0)
• EPA Substance Registry System: 4-phenylpiperidin-2-one(81976-73-0)

Safety Data

• Hazardous Substances Data: 81976-73-0(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 24, p. 1290, 1959 DOI: 10.1021/jo01091a034

Upstream product

• 5666-89-7 5-bromo-3-phenyl-valeric acid ethyl ester 
• 7664-41-7 ammonia 
• 675-20-7 piperidin-2-one 
• 771-99-3 4-phenylpiperidine 
• 98-80-6 phenylboronic acid 
• 73583-37-6 2-chloro-4-bromopyridine 
• 42260-39-9 2-chloro-4-(phenyl)pyridine 
• 51764-08-0 ethyl 2-carbethoxy-4-cyano-3-phenylbutanoate 

Downstream Products

• 1202927-36-3 2-oxo-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4'-carboxylic acid benzylamide 
• 109758-13-6 1-(3-Chloro-propyl)-4-phenyl-piperidin-2-one 
• 771-99-3 4-phenylpiperidine 
• 109758-35-2 1-(3-{4-[Bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl}-propyl)-4-phenyl-piperidin-2-one; compound with oxalic acid 
• 109757-97-3 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-4-phenyl-piperidin-2-one 

Relevant articles and documents

-

-

Transition-Metal-Free Amine Oxidation: A Chemoselective Strategy for the Late-Stage Formation of Lactams

A metal-free strategy for the formation of lactams via selective oxidation of cyclic secondary and tertiary amines is described. Molecular iodine facilitates both chemoselective and regioselective oxidation of C-H bonds directly adjacent to a cyclic amine. The mild conditions, functional group tolerance, and substrate scope are demonstrated using a suite of diverse small molecule cyclic amines, including clinically approved drug scaffolds.